Method and system for optimizing minigenes and peptides...

Details Method and system for optimizing minigenes and peptides... Method and system for optimizing minigenes and peptides...

2001-06-27

2008-12-09

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C424S192100, C702S019000, C702S020000, C530S350000

Reexamination Certificate

active

07462354

ABSTRACT:
The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of amino acid insertions at the junctions of the multi-epitope constructs so as to minimize the number of junctional epitopes and provide vaccines with increased immunogenicity.

REFERENCES:
patent: 4235877 (1980-11-01), Fullerton
patent: 4487715 (1984-12-01), Nitecki et al.
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4837028 (1989-06-01), Allen
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5128319 (1992-07-01), Arlinghaus
patent: 5200320 (1993-04-01), Sette et al.
patent: 5503829 (1996-04-01), Ladant et al.
patent: 5633234 (1997-05-01), August et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5736142 (1998-04-01), Sette et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5846827 (1998-12-01), Celis et al.
patent: 6034214 (2000-03-01), Boon et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6413517 (2002-07-01), Sette et al.
patent: 6413935 (2002-07-01), Sette et al.
patent: 6419931 (2002-07-01), Vitiello et al.
patent: 6534482 (2003-03-01), Fikes et al.
patent: 6602510 (2003-08-01), Fikes et al.
patent: 6689363 (2004-02-01), Sette et al.
patent: 2002/0098197 (2002-07-01), Sette et al.
patent: 2002/0119127 (2002-08-01), Sette et al.
patent: 2002/0160019 (2002-10-01), Sette et al.
patent: 2002/0160960 (2002-10-01), Sette et al.
patent: 2002/0168374 (2002-11-01), Kubo et al.
patent: 2002/0177694 (2002-11-01), Sette et al.
patent: 2003/0099634 (2003-05-01), Vitiello et al.
patent: 2003/0143672 (2003-07-01), Tangri et al.
patent: 2003/0152580 (2003-08-01), Sette et al.
patent: 2003/0185822 (2003-10-01), Grey et al.
patent: 2003/0203869 (2003-10-01), Fikes et al.
patent: 2003/0216342 (2003-11-01), Fikes et al.
patent: 2003/0216343 (2003-11-01), Fikes et al.
patent: 2003/0220285 (2003-11-01), Fikes et al.
patent: 2004/0096445 (2004-05-01), Sidney et al.
patent: 2004/0157273 (2004-08-01), Sidney et al.
patent: 2004/0248113 (2004-12-01), Sette et al.
patent: 2005/0049197 (2005-03-01), Sette et al.
patent: 0 044 710 (1982-01-01), None
patent: 0 226 513 (1987-06-01), None
patent: 0 429 816 (1991-06-01), None
patent: 0 433 242 (1991-06-01), None
patent: 0 378 881 (1993-06-01), None
patent: WO 92/02543 (1992-02-01), None
patent: WO 92/12996 (1992-08-01), None
patent: WO 92/21033 (1992-11-01), None
patent: WO 93/03764 (1993-03-01), None
patent: WO 93/03764 (1993-03-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/11738 (1994-05-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/04817 (1995-02-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO 95/22317 (1995-08-01), None
patent: WO 96/03140 (1996-02-01), None
patent: WO 96/2067 (1996-07-01), None
patent: WO 97/03778 (1997-02-01), None
patent: WO 97/33602 (1997-09-01), None
patent: WO 97/34617 (1997-09-01), None
patent: WO 97/34621 (1997-09-01), None
patent: WO 97/41440 (1997-11-01), None
patent: WO 98/32456 (1998-07-01), None
patent: WO 99/10646 (1999-03-01), None
patent: WO 99/45954 (1999-09-01), None
patent: WO 99/58658 (1999-11-01), None
patent: WO 99/61916 (1999-12-01), None
patent: WO 99/65522 (1999-12-01), None
patent: WO 00/19774 (2000-04-01), None
patent: WO 00/27766 (2000-05-01), None
patent: WO 01/00225 (2001-01-01), None
patent: WO 02/20616 (2002-03-01), None
patent: WO 02/061435 (2002-08-01), None
Anton et al. (1997).J Immunol158(6):2535-42.
Arndt et al. (1997).Immunol Res16(3):261-72.
Bergmann et al. (1994).J Virol. 68(8):5306-10.
Bergmann et al. (1996).J Immunol157(8):3242-9.
Bertoni et al. (1997).J Clin Invest. 100(3):503-13.
Blum et al. (1997).Crit Rev Immunol17(5-6):411-7.
Chapman, H.A. (1998).Curr Opin Immunol10(1):93-102.
Chimini et al. (1989).J Exp Med169(1):297-302.
Copier et al. (1996).J. Immunol. 157:1017-1027.
Couillin et al. (1994).J Exp Med180(3):1129-34.
Del Val et al. (1991).Cell66(6):1145-53.
Diminsky et al. (1997).Vaccine15:637-647.
Doolan et al. (1997).Immunity7(1):97-112.
Gileadi et al. (1999).Eur J Immunol29(7):2213-22.
Hahn et al. (1991).J Exp Med174(3):733-6.
Hahn et al. (1992).J Exp Med176(5):1335-41.
Hanke et al (1998).J Gen Virol79(Pt 1):83-90.
Hunt et al. (1992).Science256(5065):1817-20.
Ishioka et al. (1999).J Immunol162(7):3915-25.
Iwasaki et al. (1999).Vaccine17(15-16):2081-8.
LeBorgne et al. (1998).Virology240:304-315.
Lippolis et al. (1995).J Virol69(5):3134-46.
Livingston et al. (1997).J Immunol159(3):1383-92.
Mateo et al. (1999).J Immunol163(7):4058-63.
Moudgil et al. (1997).J Immunol159(6):2574-9.
Nakagawa et al. (1999).Immunity10(2):207-17.
Niedermann et al (1995).Immunity2(3):289-99.
Ogg G.S. et al. (1998).Curr Opin Immunol10(4):393-6.
Paz et al. (1999).Immunity11(2):241-51.
Perkins et al (1991).J Immunol146(7):2137-44.
Rammensee et al. (1995).Immunogenetics41:178-228.
Restifo et al. (1995).J Immunol154(9):4414-22.
Sette et al. (1989).J Immunol143:1268-73.
Shastri et al. (1995).J Immunol155(9):4339-46.
Theobald et al. (1998).J Exp Med188(6):1017-28.
Thomson et al. (1998).J Immunol160(4):1717-23.
Thomson et al. (1998).J Virol72(3):2246-52.
Thomson et al. (1995).Proc Natl Acad Sci USA92(13):5845-9.
Threlkeld et al. (1997).J. Immunol. 159(4):1648-57.
Tussey et al. (1995).Immunity3(1):65-77.
Wang et al. (1992).Cell Immunol143(2):284-97.
Wherry et al. (1999).J Immunol163(7):3735-45.
Woodberry et al. (1999).J Virol73(7):5320-5.
Yewdell et al. (1999).Annu Rev Immunol17:51-88.
Alexander, J., et al., “Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides,”Immunity 1:751-761, Cell Press (1994).
Barouch, D., et al., “HLA-A2 Subtypes Are Functionally Distinct in Peptide Binding and Presentation,”J. Exp. Med.182:1847-1858, Rockefeller University Press (1995).
Bender, A., et al., “Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood,”J. Immunol. Methods 196:121-135, Elsevier Science (1996).
Ben-Yedidia, T., and Arnon, R., “Design of peptide and polypeptide vaccines,”Curr. Opin. Biotechnol. 8:442-448, Current Biology, Ltd. (1997).
Carbone, F.R., and Bevan, M.J., “Induction of Ovalbumin-Specific Cytotoxic T Cells by In Vivo Peptide Immunization,”J. Exp. Med. 169:603-612, Rockefeller University Press (1989).
Carbone, F.R., et al., “Induction of Cytotoxic T Lymphocytes by Primary In Vitro Stimulation with Peptides,”J. Exp. Med. 167:1767-1779, Rockefeller University Press (1988).
Cassell, D., and Forman, J., “Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes,” Ann. N.Y. Acad. Sci.532:51-60, New York Academy Of Sciences (1991).
Deres, K., et al., “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine,” Nature 342:561-564, Nature Publishing Group (1989).
del Guercio, M-F., et al., “Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses in vivo,” Vaccine 15:441-448, Elsevier Science (Mar. 1997).
DiBrino, M., et al., “Endogenous Peptides with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8,” J. Immunol. 152:620-631, American Association of Immunologists (1994).
DiBrino, M., et al., “The HLA-B14 Peptide Binding Site Can Accommodate Peptides with Different Combinations of Anchor Residues,” J. Biol. Chem. 269:32426-32434, American Society for Biochemistry and Molecular Biology (1994).
Donnelly, J.J., et al., “DNA Vaccines,” Annu. Rev. Immunol. 15:617-648, Annual Reviews Inc. (Apr. 1997).
Francis, M.J., et al., “Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants,” Nature 330:168-170, Nature Publication Group (1987).
Fynan, E.F

Affiliated with

Also associated with

Rating

Method and system for optimizing minigenes and peptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and system for optimizing minigenes and peptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and system for optimizing minigenes and peptides... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4052311